

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/236522 A1

(51) International Patent Classification:

A61K 31/198 (2006.01) A61K 31/437 (2006.01)
A61K 31/7016 (2006.01) A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2021/032773

(22) International Filing Date:

17 May 2021 (17.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/028,874 22 May 2020 (22.05.2020) US

(71) Applicant: **OCERA THERAPEUTICS, INC.** [US/US];
c/o Mallinckrodt Pharmaceuticals, 675 McDonnell Blvd.,
Hazelwood, Missouri 63042 (US).

(72) Inventor: **VILCHEZ, Regis**; c/o Mallinckrodt Pharmaceu-
ticals, 675 McDonnell Blvd., Hazelwood, Missouri 63042
(US).

(74) Agent: **MALLON, Joseph, J.**; Knobbe, Martens, Olson &
Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California
92614 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA

(57) Abstract: Embodiments of the present disclosure relate to doses of ornithine phenylacetate for treating or ameliorating hyperammonemia and the methods of administering the same in a patient with a chronic liver disease, for example, cirrhosis. In some embodiments, the patient also has hepatic encephalopathy as a complication of the liver disease.



WO 2021/236522 A1